First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Related Keywords

Tennessee ,United States ,Nashville ,American ,Muhamed Baljevic ,Plasma Cell Disorders Research ,Division Of Hematology Oncology ,Vanderbilt Ingram Cancer Center Protocol ,Oncologic Drugs Advisory Committee ,Vanderbilt Stem Cell Transplant ,Cellular Therapy ,Vanderbilt Amyloidosis Multidisciplinary Program ,Vanderbilt Ingram Cancer Center ,Vanderbilt Ingram Cancer Center Protocol Review ,Monitoring System ,North American ,Drugs Advisory Committee ,High Risk Newly Diagnosed Multiple ,